Cerity Partners LLC boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 25.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,924 shares of the company's stock after purchasing an additional 2,202 shares during the quarter. Cerity Partners LLC's holdings in IDEXX Laboratories were worth $5,519,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in the stock. Ridgewood Investments LLC purchased a new stake in shares of IDEXX Laboratories in the second quarter worth about $27,000. Institutional & Family Asset Management LLC purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $28,000. E Fund Management Hong Kong Co. Ltd. boosted its position in shares of IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company's stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. Mowery & Schoenfeld Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 750.0% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company's stock valued at $34,000 after purchasing an additional 60 shares in the last quarter. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of IDEXX Laboratories in the second quarter valued at $36,000. 87.84% of the stock is owned by hedge funds and other institutional investors.
IDEXX Laboratories Trading Down 0.0 %
IDEXX Laboratories stock traded down $0.01 during trading hours on Friday, hitting $421.75. The company had a trading volume of 338,607 shares, compared to its average volume of 505,750. The firm has a market cap of $34.53 billion, a P/E ratio of 40.67, a P/E/G ratio of 3.68 and a beta of 1.36. The company has a 50-day moving average price of $451.91 and a two-hundred day moving average price of $478.11. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a return on equity of 55.42% and a net margin of 22.53%. The company had revenue of $975.50 million for the quarter, compared to analysts' expectations of $980.32 million. During the same quarter in the prior year, the firm earned $2.53 earnings per share. IDEXX Laboratories's revenue was up 6.6% compared to the same quarter last year. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 earnings per share for the current year.
Analyst Ratings Changes
A number of research firms recently issued reports on IDXX. Piper Sandler reaffirmed a "neutral" rating and set a $435.00 price target (down previously from $520.00) on shares of IDEXX Laboratories in a research note on Monday, November 4th. Barclays reduced their price objective on IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. decreased their price objective on IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating on the stock in a research report on Friday, October 11th. Stifel Nicolaus dropped their target price on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Finally, StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Thursday. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $552.38.
View Our Latest Analysis on IDEXX Laboratories
IDEXX Laboratories Company Profile
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Featured Stories
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
